Sawai Group Holdings Co., Ltd. (4887.T)
JPY 2033.5
(-1.09%)
JPY 2033.5
(-1.09%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 56.52 Billion JPY | 41.11% |
| 2022 | 40.05 Billion JPY | 110.47% |
| 2021 | 19.03 Billion JPY | 8.23% |
| 2020 | 17.58 Billion JPY | -14.62% |
| 2019 | 20.59 Billion JPY | -11.66% |
| 2018 | 23.31 Billion JPY | -48.57% |
| 2017 | 45.33 Billion JPY | 1662.3% |
| 2016 | -2.9 Billion JPY | -157.5% |
| 2015 | -1.12 Billion JPY | 90.11% |
| 2014 | -11.4 Billion JPY | 32.4% |
| 2013 | -16.86 Billion JPY | -206.76% |
| 2012 | 15.79 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 35.7 Billion JPY | -36.83% |
| 2023 FY | 56.52 Billion JPY | 41.11% |
| 2023 Q1 | 53.07 Billion JPY | 32.5% |
| 2023 Q2 | 49.44 Billion JPY | -6.84% |
| 2023 Q4 | 56.52 Billion JPY | -7.54% |
| 2023 Q3 | 61.12 Billion JPY | 23.63% |
| 2022 Q1 | 24.57 Billion JPY | 29.12% |
| 2022 FY | 40.05 Billion JPY | 110.47% |
| 2022 Q4 | 40.05 Billion JPY | -11.17% |
| 2022 Q3 | 45.09 Billion JPY | 75.7% |
| 2022 Q2 | 25.66 Billion JPY | 4.44% |
| 2021 Q2 | 8.71 Billion JPY | -35.17% |
| 2021 Q1 | 13.44 Billion JPY | -29.51% |
| 2021 FY | 19.03 Billion JPY | 8.23% |
| 2021 Q4 | 19.03 Billion JPY | 85.97% |
| 2021 Q3 | 10.23 Billion JPY | 17.4% |
| 2020 Q1 | 18.2 Billion JPY | -18.41% |
| 2020 FY | 17.58 Billion JPY | -14.62% |
| 2020 Q4 | 19.07 Billion JPY | -23.66% |
| 2020 Q2 | 18.28 Billion JPY | 0.45% |
| 2020 Q3 | 24.98 Billion JPY | 36.68% |
| 2019 Q3 | 28.88 Billion JPY | 16.32% |
| 2019 Q1 | 24.69 Billion JPY | 8.36% |
| 2019 Q2 | 24.83 Billion JPY | 0.56% |
| 2019 Q4 | 22.3 Billion JPY | -22.76% |
| 2019 FY | 20.59 Billion JPY | -11.66% |
| 2018 Q3 | 41 Billion JPY | -25.88% |
| 2018 FY | 23.31 Billion JPY | -48.57% |
| 2018 Q4 | 22.78 Billion JPY | -44.43% |
| 2018 Q2 | 55.32 Billion JPY | 20.41% |
| 2018 Q1 | 45.94 Billion JPY | 1.97% |
| 2017 Q4 | 45.06 Billion JPY | -43.66% |
| 2017 FY | 45.33 Billion JPY | 1662.3% |
| 2017 Q1 | 99.38 Billion JPY | 3304.77% |
| 2017 Q2 | 117.14 Billion JPY | 17.87% |
| 2017 Q3 | 79.97 Billion JPY | -31.73% |
| 2016 Q3 | 9.65 Billion JPY | 2194.3% |
| 2016 Q2 | 421 Million JPY | 114.51% |
| 2016 FY | -2.9 Billion JPY | -157.5% |
| 2016 Q4 | -3.1 Billion JPY | -132.1% |
| 2016 Q1 | -2.9 Billion JPY | 17.84% |
| 2015 Q2 | -1.21 Billion JPY | -1169.79% |
| 2015 FY | -1.12 Billion JPY | 90.11% |
| 2015 Q4 | -3.53 Billion JPY | -594.54% |
| 2015 Q3 | 714 Million JPY | 158.57% |
| 2015 Q1 | -96 Million JPY | 99.16% |
| 2014 Q1 | -9.6 Billion JPY | 43.05% |
| 2014 Q2 | -13.3 Billion JPY | -38.5% |
| 2014 Q3 | -10.59 Billion JPY | 20.38% |
| 2014 Q4 | -11.4 Billion JPY | -7.65% |
| 2014 FY | -11.4 Billion JPY | 32.4% |
| 2013 FY | -16.86 Billion JPY | -206.76% |
| 2013 Q4 | -16.86 Billion JPY | -20.34% |
| 2013 Q3 | -14.01 Billion JPY | -5987.82% |
| 2013 Q2 | 238 Million JPY | -98.71% |
| 2013 Q1 | 18.4 Billion JPY | 16.5% |
| 2012 Q3 | -22.25 Billion JPY | 10.63% |
| 2012 Q4 | 15.79 Billion JPY | 170.99% |
| 2012 Q2 | -24.89 Billion JPY | 0.0% |
| 2012 FY | 15.79 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 1.22 Billion JPY | -4514.041% |
| Takeda Pharmaceutical Company Limited | 4385.95 Billion JPY | 98.711% |
| Sumitomo Pharma Co., Ltd. | 389.83 Billion JPY | 85.501% |
| Shionogi & Co., Ltd. | -346.47 Billion JPY | 116.314% |
| Wakamoto Pharmaceutical Co.,Ltd. | -3.56 Billion JPY | 1685.862% |
| Nippon Shinyaku Co., Ltd. | -42.15 Billion JPY | 234.078% |
| Kaken Pharmaceutical Co., Ltd. | -61.47 Billion JPY | 191.945% |
| Eisai Co., Ltd. | -97.93 Billion JPY | 157.716% |
| Morishita Jintan Co., Ltd. | -667 Million JPY | 8574.063% |
| Hisamitsu Pharmaceutical Co., Inc. | -51.82 Billion JPY | 209.072% |
| Mochida Pharmaceutical Co., Ltd. | -32.92 Billion JPY | 271.69% |
| Fuso Pharmaceutical Industries,Ltd. | 7.6 Billion JPY | -643.515% |
| Nippon Chemiphar Co., Ltd. | 7.78 Billion JPY | -626.41% |
| Tsumura & Co. | 1.61 Billion JPY | -3399.814% |
| Kissei Pharmaceutical Co., Ltd. | -44.16 Billion JPY | 227.994% |
| Torii Pharmaceutical Co., Ltd. | -34.43 Billion JPY | 264.132% |
| Towa Pharmaceutical Co., Ltd. | 172.7 Billion JPY | 67.273% |
| Fuji Pharma Co., Ltd. | 26.62 Billion JPY | -112.297% |
| Zeria Pharmaceutical Co., Ltd. | 28.98 Billion JPY | -95.026% |
| KYORIN Holdings, Inc. | 7.06 Billion JPY | -700.595% |
| Taiko Pharmaceutical Co.,Ltd. | 704 Million JPY | -7928.693% |
| Daito Pharmaceutical Co.,Ltd. | 5.99 Billion JPY | -843.291% |
| SymBio Pharmaceuticals Limited | -6.51 Billion JPY | 967.3% |
| MedRx Co., Ltd | -1.72 Billion JPY | 3386.163% |
| Mizuho Medy Co.,Ltd. | -8.71 Billion JPY | 748.451% |
| Solasia Pharma K.K. | -668 Million JPY | 8561.377% |
| Modalis Therapeutics Corporation | -1.47 Billion JPY | 3942.585% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | -7.25 Billion JPY | 879.291% |
| Cyfuse Biomedical K.K. | -2.96 Billion JPY | 2009.028% |
| Toho Holdings Co., Ltd. | -98.42 Billion JPY | 157.424% |
| Koa Shoji Holdings Co.,Ltd. | -11.12 Billion JPY | 607.853% |